Saturday 6 March 2021
Home      All news      Contact us      RSS     
healtheuropa - 2 month ago

Reducing cardiovascular and cerebrovascular deaths with AstraZeneca

AstraZeneca’s recent THALES Phase III trial has demonstrated the efficacy of the drug Brilinta for reducing the risk of major cardiovascular events such as heart attacks, strokes, or cardiovascular deaths. Heart disease and stroke sit at the top of the list of leading causes of death worldwide, and yet treatments for the conditions remain limited. [ ] The post Reducing cardiovascular and cerebrovascular deaths with AstraZeneca appeared first on Health Europa.


Latest News
Hashtags:   

Reducing

 | 

cardiovascular

 | 

cerebrovascular

 | 

deaths

 | 

AstraZeneca

 | 

Sources